Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Centene (CNC) vs Humana (HUM): Weighing Two Managed Care Leaders

Centene (CNC) vs Humana (HUM): Weighing Two Managed Care Leaders

Key Takeaways

  • Centene Corporation (CNC) is the largest Medicaid-focused managed care organization with heavy exposure to the Affordable Care Act (ACA) Marketplace, while Humana Inc. (HUM) is the largest pure-play Medicare Advantage (privately managed Medicare) insurer.
  • Both stocks have rallied sharply over the past year, but CNC has posted consecutive earnings beats and guidance raises, whereas HUM remains in a reset year with adjusted earnings guided down roughly 45% year over year.
  • Tickeron AI Verdict: Based on trend consistency, earnings stability, and relative market positioning, Tickeron's AI currently favors CNC over HUM.
  • For deeper coverage of each name, explore CNC Major News and CNC Today's Price Move, as well as HUM Major News and HUM Today's Price Move.
  • To see how AI systems are applying these signals in live trading, explore the curated Trending AI Robots page.

Setting the Stage for These Two Insurers

Centene Corporation and Humana Inc. stand among the largest health insurers in the United States, yet they follow quite different paths. Centene focuses on government-sponsored Medicaid and ACA Marketplace coverage, while Humana centers on Medicare Advantage along with its CenterWell healthcare-services platform. This comparison matters for investors considering exposure across segments of the managed-care space, especially amid policy shifts, medical-cost trends, and reimbursement changes. Looking at recent performance, market positioning, and relative momentum can clarify which name currently presents the more balanced risk-and-reward outlook.

Centene’s Recent Momentum

Centene Corporation serves as the nation’s largest Medicaid managed-care provider and a significant ACA Marketplace insurer, with additional Medicare and commercial lines. In recent weeks, CNC has ranked among the stronger performers in managed care, roughly doubling from its prior-year lows and trading near its 52-week high. The latest quarterly results came in ahead of expectations, with revenue around $50.65 billion and adjusted earnings beating consensus, leading management to raise full-year adjusted EPS guidance. Analysts have lifted price targets, pointing to better Medicaid margins and progress toward Medicare breakeven. I also checked this using Tickeron’s AI Trend Prediction Engine to gauge momentum signals. Sentiment has drawn support from policy moves seen as positive for government programs. Risks remain around membership declines, higher medical costs, and regulatory uncertainty.

Humana’s Recovery Trajectory

Humana Inc. operates as the largest pure-play Medicare Advantage insurer and runs CenterWell, a growing senior primary-care and services business. HUM has posted a substantial recovery, climbing roughly 60% year to date from its 52-week low. The most recent quarter beat forecasts, with revenue rising 26% to about $41.16 billion and a narrower-than-expected adjusted loss, prompting management to raise full-year adjusted EPS guidance. A record member-weighted Medicare Star rating of 4.17 could provide a one-time boost, and membership growth is now anticipated next year. That said, Humana is working through a reset year where adjusted EPS is guided lower, carrying a higher forward valuation and greater concentration in Medicare Advantage.

Head-to-Head Differences

The main distinction lies in exposure. CNC depends heavily on Medicaid and ACA Marketplace programs, so it reacts to state reimbursement rates, enrollment policies, and subsidy rules. HUM concentrates on Medicare Advantage, tying results to federal benchmark funding, Star ratings, and senior medical-cost trends. Both have rallied, yet CNC has delivered more consistent earnings growth and trades at a lower forward valuation, while HUM carries a higher multiple against this year’s depressed earnings as the market anticipates a 2027–2028 rebound. Risk profiles vary too: HUM faces greater single-segment concentration and a near-term Stars challenge, whereas CNC deals with membership attrition and policy uncertainty across its government programs.

Tickeron AI Verdict

Overall, Tickeron’s AI currently leans toward CNC. The preference draws from a steadier upward trend, repeated earnings beats with raised guidance, improving Medicaid margins, and a more moderate valuation relative to forward earnings. While HUM offers a recovery story backed by record Star ratings and membership growth, its current-year earnings reset and richer multiple add near-term uncertainty. The AI’s edge for CNC reflects stronger trend stability and clearer relative positioning rather than any guarantee of future results.

Using Tickeron’s AI Trading Bots in Practice

When reviewing setups like these, I turn to Tickeron’s AI Trading Bots to observe how automated strategies are positioning across names in the sector. The platform offers a range of bots with different styles, timeframes, and performance histories, allowing users to match signals to their own approach. This helps highlight real-time AI-generated ideas without replacing individual analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HUM, CNC

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


HUM's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for HUM turned positive on November 10, 2026. Looking at past instances where HUM's MACD turned positive, the stock continued to rise in 36 of 50 cases over the following month. The odds of a continued upward trend are 72%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on HUM as a result. In 53 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.

Following a +5.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUM advanced for three days, in 223 of 349 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

Bearish Trend Analysis

The 10-day RSI Indicator for HUM moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 18 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 58%.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.

HUM broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 4 (best 1 - 100 worst), indicating outstanding price growth. HUM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.711) is normal, around the industry mean (3.520). P/E Ratio (40.612) is within average values for comparable stocks, (126.353). HUM's Projected Growth (PEG Ratio) (1.304) is slightly higher than the industry average of (0.786). Dividend Yield (0.008) settles around the average of (0.009) among similar stocks. P/S Ratio (0.319) is also within normal values, averaging (0.569).

The Tickeron Profit vs. Risk Rating rating for this company is 93 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 67.69B. The market cap for tickers in the group ranges from 335.99K to 353.79B. UNH holds the highest valuation in this group at 353.79B. The lowest valued company is IHGP at 335.99K.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was 2%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 16%. CVS experienced the highest price growth at 7%, while MOH experienced the biggest fall at 0%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was -43%. For the same stocks of the Industry, the average monthly volume growth was -27% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 43
Price Growth Rating: 37
SMR Rating: 72
Profit Risk Rating: 83
Seasonality Score: -6 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company offers health insurance coverage and related services

Industry ManagedHealthCare

Industry
Managed Health Care
Address
101 East Main Street
Phone
+1 502 580-1000
Employees
67060
Web
https://www.humana.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.